ResMed
 | |
| Public | |
| Traded as |
NYSE: RMD ASX: RMD |
| Industry | Medical |
| Founded | 1989 |
| Headquarters | San Diego, California |
Key people |
|
| Products | Medical equipment for sleep-disordered breathing and other respiratory disorders |
| Website | www.resmed.com |
Founded in Australia, ResMed is a global manufacturer of products for the treatment of sleep disorders, particularly obstructive sleep apnea (OSA). ResMed employs more than 4300 employees worldwide, it operates in 100 countries and has manufacturing in Australia, France, Singapore and the United States. In the fiscal year 2013/2014 it achieved revenues of US$ 1.5 billion.[1]
ResMed considers the OSA market as underpenetrated and joined a partnership with LifeScan, a Johnson & Johnson company in 2009 to increase awareness of OSA amongst type 2 diabetes patients. ResMed also raises awareness of the serious comorbidities linked to untreated sleep disorders which includes cardiovascular disease, stroke and obesity.
History
ResMed was formed in 1989, its primary purpose was to commercialise a device for treating sleep-disordered breathing with an emphasis on obstructive sleep apnea through continuous positive airway pressure (CPAP). CPAP treatment was commercialised by Peter Farrell and Professor Colin Sullivan. The company grew organically and through several acquisitions of small companies active in ventilation.[1]